Aesthetic Associates Centre Celebrates 36 Years as Buffalo's Trusted Leader in Plastic Surgery & Skin Care
'We take pride in offering a holistic, science-based approach that blends surgical precision with advanced aesthetic medicine and skin health'— Samuel Shatkin Jr., MD
BUFFALO, NY, UNITED STATES, April 12, 2025 / EINPresswire.com / -- Aesthetic Associates Centre for Plastic Surgery and Advanced Skin Care proudly marks 36 years of delivering expert care, innovation, and aesthetic transformation across Western New York. Since opening its doors in 1989, the Centre has become a leading destination for both surgical and non-surgical rejuvenation—renowned for its consistent results, clinical expertise, and compassionate approach.
Founded by the late Dr. Samuel Shatkin Sr. and now led by his son, board-certified plastic surgeon Dr. Samuel Shatkin Jr., Aesthetic Associates has built a legacy of excellence. The Centre brings together world-class surgical skills and a comprehensive aesthetic philosophy, offering a full spectrum of plastic surgery, skin care, and non-invasive treatments like Botox®, Dysport, Jeuveau and the newest product, Daxxify—all in one location.
'Our mission has always been to help patients look and feel their best through safe, individualized care,' says Dr. Shatkin. 'We take pride in offering a holistic, science-based approach that blends surgical precision with advanced aesthetic medicine and skin health.'
Supported by a highly trained team of medical and aesthetic professionals, the Centre provides treatments designed to enhance natural beauty and promote long-term wellness. Through continuous investment in advanced technologies and provider education, Aesthetic Associates remains at the forefront of innovation in cosmetic care.
The Centre is also home to the Aesthetic Learning Academy—its dedicated training platform for healthcare professionals committed to excellence in aesthetics.
Now entering its 37th year, Aesthetic Associates Centre remains a cornerstone of Buffalo's medical and cosmetic community, committed to delivering cutting-edge care and life-changing results for the next generation.
To learn more, visit www.drshatkin.com
Geron Evanson
Accelerate Dental Marketing
email us here
Visit us on social media:
X
YouTube
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Curant Rare Announces Exclusive Pharmacy Partnership for IWILFIN™, the First and Only FDA-Approved Oral Maintenance Therapy Shown to Cut the Risk of High-Risk Neuroblastoma Relapse in Half
ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare is now the exclusive pharmacy partner for IWILFIN™, a groundbreaking therapy used to reduce the risk of relapse in adults and children with high-risk neuroblastoma (HRNB). Beginning in August 2025, patients will transition to Curant Rare with one clear goal in mind: to ensure uninterrupted access to care while enhancing the patient and caregiver experience through the IWILFIN Cares® program. Beginning in August 2025, patients will transition to Curant Rare with one clear goal in mind: to ensure uninterrupted access to care while enhancing the patient and caregiver experience through the IWILFIN Cares® program. Share All patients will continue to receive IWILFIN™ as prescribed, now with an enhanced IWILFIN Cares experience powered by personalized care and digital engagement tools. This new era of clinical support delivers a seamless, elevated experience driven by advanced technology and a compassionate team of experts dedicated exclusively to high-risk neuroblastoma care. 'We're excited to launch our partnership with Curant Rare, a decision driven by one clear priority—our patients,' said Michelle Stantz, Executive Director of Market Access at US WorldMeds. 'Transitioning the IWILFIN Cares program to a new Specialty Pharmacy Partner was a tough decision and we needed to find the right partner. Curant Rare is that partner. Together, we are committed to putting patients first— ensuring our patients receive the support and treatment they need, now and into the future.' Patients and caregivers can look forward to a more connected and supportive IWILFIN Cares experience through the introduction of several features. Enhanced digital engagement will offer curated educational content to help families better understand and navigate the treatment journey. Shipment visibility tools, including real-time courier tracking and proactive shipment reminders, ensure that patients always know when to expect their medication. With smart routing and bi-directional texting, patients and caregivers can connect directly to their dedicated Patient Care Coordinator every time, helping patients and caregivers build strong, ongoing relationships with their support team and develop longitudinal care throughout their treatment journey. Additionally, insurance and financial support services will be fully managed by the Curant Rare team, including coordination of approvals, prior authorizations, and exploration of financial assistance options to help minimize out-of-pocket costs. This partnership underscores Curant Rare's commitment and dedication to delivering exceptional, patient-centered care for families navigating high-risk neuroblastoma. By ensuring uninterrupted access to therapy, Curant Rare empowers patients and caregivers with unparalleled support, seamless communication, and a transformative, modern care experience. For more information on the IWILFIN Cares program, patients and families are encouraged to contact Curant Rare at 877-IWILFIN (877-494-5346) or visit About Curant Rare Curant Rare, a specialized Curant Health Business Unit, provides bespoke specialty pharmacy and Real-World Evidence solutions to provide best-in-class rare disease patient and provider journeys. Curant Rare's personalized approach to patient care focuses on rare and ultra-rare patient populations to improve outcomes in measurable and meaningful ways. Curant Rare provides comprehensive high-quality care while placing the patient's physical and psychosocial well-being as a priority through their validated Medication Care Management® services. With over 25 years of experience, Curant Rare brings a proven track record in best-in-class patient adherence and Quality of Life. About US WorldMeds US WorldMeds is a privately held specialty pharmaceutical company that develops, licenses, and markets unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs. More information on US WorldMeds can be found at IWILFIN is a registered trademark of USWM, LLC. US WORLDMEDS is a registered trademark of USWM, LLC. USWMIWI-00043 12/2023 IMPORTANT SAFETY INFORMATION Indication IWILFIN is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. Warnings and Precautions IWILFIN can cause myelosuppression and hepatotoxicity. CBC and liver function tests should be performed before starting treatment and as clinically indicated for the duration of treatment. Withhold, reduce the dose, or permanently discontinue IWILFIN based on severity. IWILFIN can cause hearing loss. Monitor hearing before and during treatment with IWILFIN. Withhold, reduce the dose, or permanently discontinue IWILFIN based on severity. IWILFIN can cause fetal harm. Advise females of reproductive potential of the possible risk to a fetus and to use effective contraception. Adverse Reactions The most common (≥5%) adverse reactions are hearing loss, otitis media, pyrexia, pneumonia, and diarrhea. The most common (≥2%) Grade 3 or 4 laboratory abnormalities are increased ALT, increased AST, decreased neutrophil count, and decreased hemoglobin.
Business Wire
3 hours ago
- Business Wire
Atropos Health Enters into Strategic Collaboration to Reduce Time to Rare Disease Diagnosis with Artificial Intelligence (AI) Algorithm
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, today announced a collaboration with Novartis. Through this strategic collaboration, Atropos Health will build, train and evaluate multiple models to help streamline identification of people with a rare disease who have not yet been diagnosed, ultimately reducing time from symptom reporting to testing, diagnosis and treatment. The collaboration will specifically focus on paroxysmal nocturnal hemoglobinuria (PNH), a rare, serious blood disorder. Adults with PNH often experience lengthy diagnostic delays—many wait over a year, and some more than five—because the disease is rare and presents varied symptoms affecting multiple organs. 1,2 As a part of this collaboration, Atropos Health has developed an initial AI model for finding potential patients with PNH who have not yet been diagnosed, aimed to save critical time for both patients and providers by helping health systems accelerate appropriate diagnosis. The AI model is now available for integration into health systems. 'Building AI models tested and trained on high-quality real-world data is truly the next frontier in precision medicine,' said Dr. Brigham Hyde, CEO and co-founder at Atropos Health. 'The accuracy of the models reduces the guesswork and patients who are able to get testing sooner provides a potentially life-changing experience. For providers and health systems, faster time to diagnosis and treatment equate to higher patient satisfaction.' The goal of the strategic collaboration is to build and publish patient-finding models aimed at reducing time from initial symptoms to testing, diagnosis and treatment. The models created by Atropos Health in connection with this collaboration will be implemented across health system members of the Atropos Evidence Network and be seamlessly integrated at the point of care to improve the provider and patient experience. Through this collaboration, Atropos Health will build models trained on real-world data (RWD) from the Atropos Evidence™ Network, which includes GENEVA OS ®. 'At Novartis, we are committed to delivering meaningful impact for patients. Accelerating diagnosis and treatment through AI and machine learning has the power to significantly improve patient outcomes by enabling faster access to appropriate care,' said Rodney Gillespie, Head of Oncology, Novartis US. 'Our collaboration with Atropos Health to develop an AI model for identifying PNH embodies this commitment as it advances precision health, potentially enabling earlier diagnosis and timely care, reducing delays that can greatly affect patients' lives.' About paroxysmal nocturnal hemoglobinuria (PNH) PNH is a rare, chronic and serious complement-mediated blood disorder 3. People with PNH have an acquired mutation in some of their hematopoietic stem cells (which are located in the bone marrow and can grow and develop into red blood cells [RBCs], white blood cells and platelets) that causes them to produce RBCs that are susceptible to premature destruction by the complement system. 4 It is estimated that approximately 10-20 people per million worldwide live with PNH. Although PNH can develop at any age, it is often diagnosed in people between 30-40 years old. 5,6 Today's announcement follows Atropos Health's AI model training capabilities released earlier this year. Atropos Evidence Network membership benefits include the ability to leverage the network to deliver AI models to clinicians. Atropos Health is collaborating with Arcadia to help leading healthcare organizations deliver the latest care protocols and advanced precision medicine at scale. The partnership enables healthcare providers to accelerate clinical decision-making with actionable, AI-powered insights at the point of care using the combination of real-world evidence (RWE) and longitudinal patient records to improve outcomes and drive high-value, low-cost care. Healthcare organizations are also engaged with Atropos Health on leveraging AI for precision medicine, and building MOTOR, CLMBR and Foundation models on the Atropos Evidence Network. About Atropos Health Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit or connect through LinkedIn or follow on X (Twitter) @AtroposHealth. _________________________ 1 Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S8-S14. doi: 10.18553/jmcp.2020.26.12-b.s8. PMID: 33356781; PMCID: PMC10408416 2 Mancuso S, Sucato G, Carlisi M, Santoro M, Tarantino G, Iannitto E, Napolitano M, Siragusa S. Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs. Hematol Rep. 2018 Mar 29;10(1):7523. doi: 10.4081/hr.2018.7523. PMID: 29721255; PMCID: PMC5907647. 3 Cançado RD, Araújo ADS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341-348. 4 Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101(2):251-263. 5 Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. 6 Röth A, Maciejewski J, Nishimura JI, Jain D, Weitz JI. Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018;101(1):3-11. Expand
Business Wire
3 hours ago
- Business Wire
GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic
BUSINESS WIRE)-- GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic ® (semaglutide) and Wegovy ® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today. This collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those who lack adequate insurance coverage. Today also marks the first time Ozempic ® has been made available to patients at this self-pay price. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' said Wendy Barnes, President and Chief Executive Officer of GoodRx. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them. It's a powerful example of how the GoodRx platform can deliver savings at scale—bridging gaps in coverage and ensuring more people can get the care they deserve.' In the last year, almost 17 million people came to GoodRx looking for savings and information on GLP-1 medications, a 22% increase from the previous year. Now, GoodRx is poised to more effectively meet this growing demand by leveraging the extensive reach and scale of its trusted platform to deliver savings directly to patients who need them. This collaboration represents a significant milestone in improving access and affordability of these important, authentic, FDA-approved medications. 'Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform,' said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. 'This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic ® self-pay offer for type 2 diabetes patients at an unprecedented price.' Healthcare professionals are increasingly prescribing these groundbreaking medications to support patients diagnosed with type 2 diabetes or obesity—yet insurance coverage remains a challenge for many seeking treatment, especially those seeking obesity medications. For example, GoodRx research shows 19 million people lack coverage for any GLP-1s prescribed for weight loss. By filling the gaps in insurance coverage, GoodRx is playing a critical role in reducing friction in the system and helping accelerate speed to therapy so consumers can benefit from these critical treatments. Starting today, eligible patients can use GoodRx to self-pay for Ozempic ® and Wegovy ® pens for $499-per-month at over 70,000 retail pharmacies nationwide. To learn more, visit: or About GoodRx GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $85 billion on the cost of their medications. GoodRx periodically posts information that may be important to investors on its investor relations website at We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission (the 'SEC') and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release. GoodRx Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of our offerings to consumers, GoodRx, Novo Nordisk and other pharmaceutical manufacturers. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
